{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:47:01Z","timestamp":1791920821118,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010426","name":"UGC-DAE\u00a0Consortium for Scientific Research, University Grants Commission","doi-asserted-by":"publisher","award":["F.5-15\/2016\/DRS-1"],"award-info":[{"award-number":["F.5-15\/2016\/DRS-1"]}],"id":[{"id":"10.13039\/501100010426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["DBT\/2016\/UOH\/697"],"award-info":[{"award-number":["DBT\/2016\/UOH\/697"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00280-023-04524-9","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T03:30:46Z","timestamp":1680060646000},"page":"375-387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Synergistic action of lactoferrin in enhancing the safety and effectiveness of docetaxel treatment against prostate cancer"],"prefix":"10.1007","volume":"91","author":[{"given":"Chukhu","family":"Muj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyajit","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritikana","family":"Jana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0711-3126","authenticated-orcid":false,"given":"Anand K.","family":"Kondapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"4524_CR1","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.mgene.2014.07.007","volume":"2","author":"S Jain","year":"2014","unstructured":"Jain S, Saxena S, Kumar A (2014) Epidemiology of prostate cancer in India. Meta Gene 2:596\u2013605","journal-title":"Meta Gene"},{"key":"4524_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10:63\u201389","journal-title":"World J Oncol"},{"key":"4524_CR3","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2017.7248","volume":"317","author":"MS Litwin","year":"2017","unstructured":"Litwin MS, Tan HJ (2017) The diagnosis and treatment of prostate cancer: a review. JAMA J Am Med Assoc 317:2532\u20132542","journal-title":"JAMA J Am Med Assoc"},{"key":"4524_CR4","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino \u00c1, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, M\u00e9ndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386:1132\u20131142","journal-title":"N Engl J Med"},{"key":"4524_CR5","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A (2022) Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet 399:1695\u20131707","journal-title":"Lancet"},{"key":"4524_CR6","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1200\/JCO.2010.30.7025","volume":"28","author":"RM Franke","year":"2010","unstructured":"Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A (2010) Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 28:4562","journal-title":"J Clin Oncol"},{"key":"4524_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201904997","volume":"31","author":"L Chen","year":"2019","unstructured":"Chen L, Zhou L, Wang C, Han Y, Lu Y, Liu J, Hu X, Yao T, Lin Y, Liang S, Shi S, Dong C (2019) Tumor-targeted drug and CpG delivery system for phototherapy and docetaxel-enhanced immunotherapy with polarization toward M1-type macrophages on triple negative breast cancers. Adv Mater 31:1904997","journal-title":"Adv Mater"},{"key":"4524_CR8","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2147\/IJN.S121881","volume":"12","author":"P Rafiei","year":"2017","unstructured":"Rafiei P, Haddadi A (2017) Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile. Int J Nanomedicine 12:935","journal-title":"Int J Nanomedicine"},{"key":"4524_CR9","unstructured":"About the influence of PEG spacers on the cytotoxicity of titanate nanotubes-docetaxel nanohybrids against a prostate cancer cell line.pdf"},{"key":"4524_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13130","volume":"54","author":"L Dai","year":"2021","unstructured":"Dai L, Wei D, Zhang J, Shen T, Zhao Y, Liang J, Ma W, Zhang L, Liu Q, Zheng Y (2021) Aptamer-conjugated mesoporous polydopamine for docetaxel targeted delivery and synergistic photothermal therapy of prostate cancer. Cell Prolif 54:e13130","journal-title":"Cell Prolif"},{"key":"4524_CR11","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.2147\/DDDT.S366622","volume":"16","author":"Z Dong","year":"2022","unstructured":"Dong Z, Wang Y, Guo J, Tian C, Pan W, Wang H, Yan J (2022) Prostate cancer therapy using docetaxel and formononetin combination: hyaluronic acid and epidermal growth factor receptor targeted peptide dual ligands modified binary nanoparticles to facilitate the in vivo anti-tumor activity. Drug Des Dev Ther 16:2683\u20132693","journal-title":"Drug Des Dev Ther"},{"key":"4524_CR12","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1111\/j.1349-7006.2000.tb00880.x","volume":"91","author":"WP Wang","year":"2000","unstructured":"Wang WP, Iigo M, Sato J, Sekine K, Adachi I, Tsuda H (2000) Activation of intestinal mucosal immunity in tumor-bearing mice by lactoferrin. Jpn J Cancer Res 91:1022","journal-title":"Jpn J Cancer Res"},{"key":"4524_CR13","unstructured":"Asian Pacific Journal of Cancer Prevention [online]. http:\/\/journal.waocp.org\/?sid=Entrez:PubMed&id=pmid:12716300&key=2000.1.4.277 (Accessed 10 Sep 2022)"},{"key":"4524_CR14","unstructured":"Bermudez LE, Martinez-Zaguil\u00e1n R, Filleur S, Perez-Zoghbi J (2010) V-ATPase at the cell surface in highly metastatic prostate cancer Cells [online]. https:\/\/ttu-ir.tdl.org\/handle\/2346\/ETD-TTU-2010-12-1286 (Accessed 10 Sep 2022)"},{"key":"4524_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3389\/fonc.2018.00200","volume":"8","author":"JP Guedes","year":"2018","unstructured":"Guedes JP, Pereira CS, Rodrigues LR, C\u00f4rte-Real M (2018) Bovine milk lactoferrin selectively kills highly metastatic prostate cancer PC-3 and osteosarcoma MG-63 cells in vitro. Front Oncol 8:200","journal-title":"Front Oncol"},{"key":"4524_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2021.692117","volume":"11","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Cheng Y, Xiong Y (2021) LTF regulates the immune microenvironment of prostate cancer through JAK\/STAT3 pathway. Front Oncol 11:1\u201312","journal-title":"Front Oncol"},{"key":"4524_CR17","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2020-0090.15,2071-2083","author":"AK Kondapi","year":"2020","unstructured":"Kondapi AK (2020) Targeting cancer with lactoferrin nanoparticles: recent advances. Nanomedicine. https:\/\/doi.org\/10.2217\/nnm-2020-0090.15,2071-2083","journal-title":"Nanomedicine"},{"key":"4524_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120355","volume":"263","author":"AO Elzoghby","year":"2020","unstructured":"Elzoghby AO, Abdelmoneem MA, Hassanin IA, Abd Elwakil MM, Elnaggar MA, Mokhtar S, Fang JY, Elkhodairy KA (2020) Lactoferrin, a multi-functional glycoprotein: active therapeutic, drug nanocarrier and targeting ligand. Biomaterials 263:120355","journal-title":"Biomaterials"},{"key":"4524_CR19","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.2147\/IJN.S316830","volume":"16","author":"J Almowalad","year":"2021","unstructured":"Almowalad J, Somani S, Laskar P, Meewan J, Tate RJ, Mullin M, Duf\u00e8s C (2021) Lactoferrin-bearing gold nanocages for gene delivery in prostate cancer cells in vitro. Int J Nanomedicine 16:4391\u20134407","journal-title":"Int J Nanomedicine"},{"key":"4524_CR20","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.2147\/IJN.S347574","volume":"17","author":"J Almowalad","year":"2022","unstructured":"Almowalad J, Laskar P, Somani S, Meewan J, Tate RJ, Duf\u00e8s C (2022) Lactoferrin- and dendrimer-bearing gold nanocages for stimulus-free DNA delivery to prostate cancer cells. Int J Nanomedicine 17:1409\u20131421","journal-title":"Int J Nanomedicine"},{"key":"4524_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051960","author":"K Golla","year":"2012","unstructured":"Golla K, Cherukuvada B, Ahmed F, Kondapi AK (2012) Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats. PLoS\u00a0One. https:\/\/doi.org\/10.1371\/journal.pone.0051960","journal-title":"PLoS\u00a0One."},{"key":"4524_CR22","doi-asserted-by":"publisher","first-page":"644","DOI":"10.7150\/jca.7093","volume":"4","author":"K Golla","year":"2013","unstructured":"Golla K, Bhaskar C, Ahmed F, Kondapi AK (2013) A target-specific oral formulation of doxorubicin-protein nanoparticles: efficacy and safety in hepatocellular cancer. J Cancer 4:644\u2013652","journal-title":"J Cancer"},{"key":"4524_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2016.10.110","author":"S Kumari","year":"2017","unstructured":"Kumari S, Kondapi AK (2017) Lactoferrin nanoparticle mediated targeted delivery of 5-fluorouracil for enhanced therapeutic efficacy. Int J Biol Macromol. https:\/\/doi.org\/10.1016\/j.ijbiomac.2016.10.110","journal-title":"Int J Biol Macromol"},{"key":"4524_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/S11095-018-2457-7","author":"F Ahmed","year":"2018","unstructured":"Ahmed F, Kumari S, Kondapi AK (2018) Evaluation of antiproliferative activity, safety and biodistribution of oxaliplatin and 5-fluorouracil loaded lactoferrin nanoparticles for the management of colon adenocarcinoma: an in vitro and an in vivo study. Pharm Res. https:\/\/doi.org\/10.1007\/S11095-018-2457-7","journal-title":"Pharm Res"},{"key":"4524_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-06888-4","volume":"7","author":"S Kumari","year":"2017","unstructured":"Kumari S, Ahsan SM, Kumar JM, Kondapi AK, Rao NM (2017) Overcoming blood brain barrier with a dual purpose temozolomide loaded lactoferrin nanoparticles for combating glioma (SERP-17-12433). Sci Rep 7:1\u201313","journal-title":"Sci Rep"},{"key":"4524_CR26","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ijbiomac.2014.07.041","volume":"70","author":"F Ahmed","year":"2014","unstructured":"Ahmed F, Ali MJ, Kondapi AK (2014) Carboplatin loaded protein nanoparticles exhibit improve anti-proliferative activity in retinoblastoma cells. Int J Biol Macromol 70:572\u2013582","journal-title":"Int J Biol Macromol"},{"key":"4524_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1167\/iovs.62.14.13","volume":"62","author":"RVL Narayana","year":"2021","unstructured":"Narayana RVL, Jana P, Tomar N, Prabhu V, Nair RM, Manukonda R, Kaliki S, Coupland SE, Alexander J, Kalirai H, Kondapi AK, Vemuganti GK (2021) Carboplatin- and etoposide-loaded lactoferrin protein nanoparticles for targeting cancer stem cells in retinoblastoma in vitro. Investig Ophthalmol Vis Sci 62:13\u201313","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4524_CR28","first-page":"1760","volume":"54","author":"R Bannerji","year":"1994","unstructured":"Bannerji R, Rosenthal FM, Heston WDW, Fair WR, Gansbacher B, Gilboa E (1994) Immunotherapy of prostate cancer in the dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 54:1760\u20131765","journal-title":"Cancer Res"},{"key":"4524_CR29","doi-asserted-by":"publisher","DOI":"10.22159\/ijap.2018v10i6.28004","author":"H Athmakur","year":"2018","unstructured":"Athmakur H, Kondapi AK (2018) Carmustine loaded lactoferrin nanoparticles demonstrates an enhanced antiproliferative activity against glioblastoma in vitro. Int J Appl Pharm. https:\/\/doi.org\/10.22159\/ijap.2018v10i6.28004","journal-title":"Int J Appl Pharm"},{"key":"4524_CR30","doi-asserted-by":"publisher","DOI":"10.1021\/mp800051m","author":"F Alexis","year":"2008","unstructured":"Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. https:\/\/doi.org\/10.1021\/mp800051m","journal-title":"Mol Pharm"},{"key":"4524_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140399","author":"P Kumar","year":"2015","unstructured":"Kumar P, Lakshmi YS, Bhaskar C, Golla K, Kondapi AK (2015) Improved safety, bioavailability and pharmacokinetics of zidovudine through lactoferrin nanoparticles during oral administration in rats. PLoS\u00a0One. https:\/\/doi.org\/10.1371\/journal.pone.0140399","journal-title":"PLoS\u00a0One."},{"key":"4524_CR32","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ijbiomac.2017.11.160","volume":"108","author":"S Kumari","year":"2018","unstructured":"Kumari S, Kondapi AK (2018) Receptor-mediated targeted delivery of DNA using lactoferrin nanoparticles. Int J Biol Macromol 108:401\u2013407","journal-title":"Int J Biol Macromol"},{"key":"4524_CR33","doi-asserted-by":"publisher","first-page":"L257","DOI":"10.1152\/ajplung.1999.277.2.L257","volume":"277","author":"IM Smirnov","year":"2022","unstructured":"Smirnov IM, Bailey K, Flowers CH, Garrigues NW, Wesselius LJ, Igor M (2022) Effects of TNF-\u03b1 and IL-1 \u03b2 on iron metabolism by A549 cells and influence on cytotoxicity. Am J Physiol Lung Cell Mol Physiol 277:L257\u2013L263","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"4524_CR34","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1016\/j.biomaterials.2007.04.011","volume":"28","author":"M Elfinger","year":"2007","unstructured":"Elfinger M, Maucksch C, Rudolph C (2007) Characterization of lactoferrin as a targeting ligand for nonviral gene delivery to airway epithelial cells. Biomaterials 28:3448\u20133455","journal-title":"Biomaterials"},{"key":"4524_CR35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12032-014-0923-6","volume":"31","author":"U Uyeturk","year":"2014","unstructured":"Uyeturk U, Sar\u0131c\u0131 H, K\u0131n Tekce B, Eroglu M, Kemahl\u0131 E, Uyeturk U, Gucuk A (2014) Serum omentin level in patients with prostate cancer. Med Oncol 31:6\u201310","journal-title":"Med Oncol"},{"key":"4524_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3852401","author":"M Fryczkowski","year":"2018","unstructured":"Fryczkowski M, Bu\u0142dak RJ, Hejmo T, Kukla M, Zwirska-Korczala K (2018) Circulating levels of omentin, leptin, VEGF, and HGF and their clinical relevance with PSA marker in prostate cancer. Dis Mark. https:\/\/doi.org\/10.1155\/2018\/3852401","journal-title":"Dis Mark"},{"key":"4524_CR37","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejpb.2016.07.007","volume":"107","author":"Z Chen","year":"2016","unstructured":"Chen Z, Tai Z, Gu F, Hu C, Zhu Q, Gao S (2016) Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy. Eur J Pharm Biopharm 107:130\u2013141","journal-title":"Eur J Pharm Biopharm"},{"key":"4524_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"Q Wang","year":"2017","unstructured":"Wang Q, Alshaker H, B\u00f6hler T, Srivats S, Chao Y, Cooper C, Pchejetski D (2017) Core shell lipid\u2013polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer. Sci Rep 7:1\u20138","journal-title":"Sci Rep"},{"key":"4524_CR39","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3892\/mmr.2014.2914","volume":"11","author":"LT Li","year":"2015","unstructured":"Li LT, Jiang G, Chen Q, Zheng JN (2015) Predic Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep 11:1566\u20131572","journal-title":"Mol Med Rep"},{"key":"4524_CR40","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/s41379-019-0260-6","volume":"32","author":"P Hammarsten","year":"2019","unstructured":"Hammarsten P, Josefsson A, Thysell E, Lundholm M, H\u00e4ggl\u00f6f C, Iglesias-Gato D, Flores-Morales A, Stattin P, Egevad L, Granfors T, Wikstr\u00f6m P, Bergh A (2019) Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome. Mod Pathol 32:1310\u20131319","journal-title":"Mod Pathol"},{"key":"4524_CR41","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1200\/JCO.2006.05.9501","volume":"24","author":"MI Koukourakis","year":"2006","unstructured":"Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL (2006) Lactate dehydrogenase 5 expression in operable colorectal cancer: Strong association with survival and activated vascular endothelial growth factor pathway\u2014a report of the tumour angiogenesis research group. J Clin Oncol 24:4301\u20134308","journal-title":"J Clin Oncol"},{"key":"4524_CR42","doi-asserted-by":"publisher","first-page":"7341","DOI":"10.1002\/cam4.3108","volume":"9","author":"F Li","year":"2020","unstructured":"Li F, Xiang H, Pang Z, Chen Z, Dai J, Chen S, Xu B, Zhang T (2020) Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: a meta-analysis. Cancer Med 9:7341","journal-title":"Cancer Med"},{"key":"4524_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/160835","author":"HY Ren","year":"2015","unstructured":"Ren HY, Sun LL, Li HY, Ye ZM (2015) Prognostic significance of serum alkaline phosphatase level in osteosarcoma: a meta-analysis of published data. Biomed Res Int. https:\/\/doi.org\/10.1155\/2015\/160835","journal-title":"Biomed Res Int"},{"key":"4524_CR44","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.2147\/CMAR.S174237","volume":"10","author":"D Li","year":"2018","unstructured":"Li D, Lv H, Hao X, Hu B, Song Y (2018) Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: evidence from a meta-analysis. Cancer Manag Res 10:3125","journal-title":"Cancer Manag Res"},{"key":"4524_CR45","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.2217\/nnm.15.107","volume":"10","author":"H Kulhari","year":"2015","unstructured":"Kulhari H, Pooja D, Singh MK, Kuncha M, Adams DJ, Sistla R (2015) Bombesin-conjugated nanoparticles improve the cytotoxic efficacy of docetaxel against gastrin-releasing but androgen-independent prostate cancer. Nanomedicine 10:2847\u20132859","journal-title":"Nanomedicine"},{"issue":"9","key":"4524_CR46","first-page":"1","volume":"91","author":"D Rosenblum","year":"2018","unstructured":"Rosenblum D, Joshi N, Tao W, Karp JM, Peer D (2018) Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun 91(9):1\u201312","journal-title":"Nat Commun"},{"key":"4524_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47308-z","volume":"9","author":"W Zhang","year":"2019","unstructured":"Zhang W, Fan W, Rachagani S, Zhou Z, Lele SM, Batra SK, Garrison JC (2019) Comparative study of subcutaneous and orthotopic mouse models of prostate cancer: vascular perfusion, vasculature density, hypoxic burden and BB2r-targeting efficacy. Sci Rep 9:11117","journal-title":"Sci Rep"},{"key":"4524_CR48","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1080\/10717544.2018.1440666","volume":"25","author":"N Altwaijry","year":"2018","unstructured":"Altwaijry N, Somani S, Parkinson JA, Tate RJ, Keating P, Warzecha M, Mackenzie GR, Leung HY, Duf\u00e8s C (2018) Regression of prostate tumors after intravenous administration of lactoferrin-bearing polypropylenimine dendriplexes encoding TNF-\u03b1, TRAIL, and interleukin-12. Drug Deliv 25:679\u2013689","journal-title":"Drug Deliv"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04524-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04524-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04524-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T02:02:31Z","timestamp":1683165751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04524-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["4524"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04524-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"assertion":[{"value":"15 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"We have included all data in the main manuscript, Figures and Supplementary Information, there no additional data that is available or deposited in any database.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}